Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Health

Predicine and Merck KGaA, Darmstadt, Germany to Present Data at AACR – Advances in Liquid Biopsy Conference 2020

Leave a comment


We are very delighted to work with Merck KGaA, Darmstadt, Germany, a precision medicine driven company. We have a shared vision of the critical role of liquid biopsy in revolutionizing personalized cancer treatments and clinical drug development.


HAYWARD, Calif. (PRWEB)

Predicine, a molecular insights company headquartered in Hayward, California, with global footprints in China, today announced results from a collaborative biomarker study with Merck KGaA, Darmstadt, Germany, a leading science and technology company operating its biopharmaceuticals business in the U.S. and Canada as EMD Serono, will be jointly presented at the American Association for Cancer Research (AACR) – Advances in Liquid Biopsies Conference, taking place from January 13 to 16, 2020 in Miami, Florida. The study explores the potential clinical utility of Predicine’s proprietary liquid biopsy platforms for detection of genetic alterations using plasma-derived circulated tumor DNA (ctDNA) and cell-free RNA (cfRNA) in patients with advanced colorectal cancer (CRC).

Highlights of this study include:


  • The clinical feasibility of simultaneous multiparametric profiling using a combined cfDNA and cfRNA liquid biopsy approach for molecular characterization in advanced CRC.

  • cfRNA-derived variant detection confirms the variants originally detected in cfDNA test and validates the high specificity results for report interpretation.

  • cfDNA-based detection of tumor mutation burden (TMB).

Data to be presented also support the role of clinical implementation of a combined cfDNA and cfRNA test that could provide holistic molecular insight for detecting cancer driver mutations, monitoring efficacy/disease burden, as well as identifying sub-clonal alterations that may be relevant to drug resistance and tumor heterogeneity.

“We are very delighted to work with Merck KGaA, Darmstadt, Germany, a precision medicine driven company. We have a shared vision of the critical role of liquid biopsy in revolutionizing personalized cancer treatments and clinical drug development,” said Dr. Shidong Jia, Founder and CEO at Predicine. “Predicine’s next-generation sequencing-based comprehensive non-invasive liquid biopsy platform adds value by enabling biomarker-driven patient selection & enrollment, longitudinal disease monitoring and exploring the new paradigm for both targeted and combination therapies.”

About Predicine

Predicine is a molecular insights company that is committed to advancing biomarker-driven precision medicine. Predicine has developed a breakthrough RNA- and DNA-based liquid biopsy technology for non-invasive cancer profiling, disease monitoring and assessing minimal residual disease. Through its CLIA and/or CAP facilities in the US and China, Predicine partners with leading biopharma companies and hospitals to support global clinical trials and personalized cancer therapy.

Share article on social media or email:

health and fitness

Piada Expands Menu to Include Keto, Paleo and High-Protein Options, Making it More Inclusive for all Guests

Leave a comment


Keto BLT Salad

“These new additions to the menu make Piada more accessible to all Guests,” said Chris Doody, Piada founder.


COLUMBUS, Ohio (PRWEB)

Piada Italian Street Food welcomes everyone to its table with the debut of its new lifestyle menu items, including keto, paleo and high-protein options, which guests can order online only starting today at mypiada.com/order.

“These new additions to the menu make Piada more accessible to all Guests,” said Chris Doody, Piada founder. “Whether Guests have a restricted diet for health reasons or are just trying to establish different eating habits at the start of the new year, these new dishes open up the menu for everyone to enjoy something at Piada.”

By offering these new menu items online only for in-store pickup, Piada’s culinary team can ensure precise measuring and preparation of the food. This allows for accuracy in every dish, giving Guests exactly what they want.

The new lifestyle items include:

  • Keto BLT Salad – Roasted bruschetta tomatoes, whole milk mozzarella and four pieces of crispy pancetta crumbled onto a bed of chopped romaine, tossed in Piada’s signature house-made creamy parmesan dressing.

  • Paleo Berry Balsamic Salad – Creamy avocado and fresh sliced strawberries mixed with red cabbage and spinach tossed in their new berry balsamic dressing.

  • Protein Bowl – Piada’s all-natural white meat chicken is topped with whole milk mozzarella, house-made basil pesto and roasted bruschetta tomatoes, served aside roasted broccoli and sautéed zucchini and mushrooms. It’s packed with 50 grams of protein in each bowl!

Piada fans with restricted diets or specific dietary preferences understand and appreciate the importance of measuring and handling ingredients carefully when preparing paleo and keto dishes. To ensure the accuracy and safety of these new dishes, Piada works with MenuTrinfo®, a nationally recognized allergen and gluten-free company, to train their staff.

“Over the last few years, we took a step back from our growth agenda to refocus on our core values and getting it right for our Guests,” said Doody. “Maintaining the quality of our core menu items like our Piadas and signature pasta dishes will always be a priority, but we are constantly looking for ways to tweak and improve our menu so that all feel welcome.”

Later this month, Piada will introduce a revamped version of their gluten-free, vegetarian/vegan Power Bowl featuring roasted vegetables, avocado and pickled onions over a bed of warm quinoa.

Throughout the year, Piada plans to introduce additional items to its menu to fit a variety of lifestyles, so Guests should keep their eyes peeled for what’s coming next!

About Piada

The restaurant’s premium fast-casual concept, which offers Guests an array of healthy (and indulgent) options from a selection of more than 30 toppings, is centered around the Piada. Piadas are made up of a thin-crust dough, which is freshly baked on a stone grill and filled with a selection of Italian-inspired ingredients, then hand-rolled to perfection. Other signature menu items include Piada’s salads made with fresh ingredients and craveable pasta dishes made with their house-made sauces.

As a chef-driven concept, Piada’s food is cooked under classic culinary standards and emphasizes using ingredients that are fresh and of the highest quality. Recipes are inspired by traditional, simple Italian cooking techniques and highlight flavors like basil, rosemary and San Marzano tomatoes.

Piada was inspired by the roadside family-run street food carts and markets found in Rimini, Italy, and the company’s first restaurant opened in 2010. Headquartered in Columbus, Ohio, Piada has 40 locations throughout Ohio, Indiana and Michigan, Kentucky, Pennsylvania, Minnesota and Texas. For more information, visit MyPiada.com or follow Piada on Facebook, Twitter, and Instagram.

Editor’s note: High resolution photos are available for download here.

###

Media Contact:

Emily Hanhart, 330-407-0776, emily@inspireprgroup.com

Share article on social media or email:

Industry: Healthcare

CytomX Therapeutics Deploys Genedata Bioprocess

Leave a comment


News Image

Our decision to adopt the Genedata Bioprocess platform is based on its ability to directly integrate with our laboratory equipment and automate all data transfer, capture, processing, and data analysis and interpretation.


SAN FRANCISCO (PRWEB)

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that CytomX Therapeutics, a clinical-stage oncology-focused biopharmaceutical company, has licensed Genedata Bioprocess® to act as an integrated workflow backbone for its bioprocess development operations. CytomX will use Genedata Bioprocess to streamline and automate its process development workflows and to make the development of next-generation production processes more efficient.

“As our portfolio of novel drug candidates continues to rapidly expand, we needed to ramp up our development operations to keep pace. Genedata Bioprocess ensures the upscaling of our new drug manufacturing processes,” said Sridhar Viswanathan, Ph.D., Senior Vice President, Process Sciences and Manufacturing Operations at CytomX Therapeutics. “Our decision to adopt the Genedata Bioprocess platform is based on its ability to directly integrate with our laboratory equipment and automate all data transfer, capture, processing, and data analysis and interpretation. By enabling true high-throughput processes, we can significantly reduce time, effort, and costs within our daily operations.”

Genedata Bioprocess has been implemented in CytomX’s process development groups, with a focus on managing and interpreting bioreactor online and offline data. In particular, the platform will be used for CytomX’s novel class of antibody therapeutics based on its Probody™ therapeutic technology platform. Genedata Bioprocess will be used across all R&D programs at CytomX, including both proprietary and partnered R&D programs.

End-to-end (E2E) Workflow Platform for Bioprocess Development & CMC

Co-developed over the last six years with major biopharmaceutical companies, Genedata Bioprocess has been adopted by large, multinational biopharmaceutical companies and CMOs, as well as by smaller, innovative biotechnology organizations. The platform integrates all data generated along the biopharmaceutical development and CMC process, including upstream (USP), downstream (DSP), and analytics functions. It enables fully-automated processes, such as streamlining highly parallelized scale-down expression experiments in ambr® mini-bioreactors and data processing for large-scale bioreactors. In addition, by providing a central platform, it accelerates and improves the drug candidate’s transition from research to development. Built on a modular and scalable architecture, the platform is suitable for installations ranging from single-site groups to global, multi-site biopharma development organizations.

“We are delighted that CytomX, a leader with an innovative oncology drug development platform, has implemented Genedata Bioprocess to streamline their biopharma development operations,” said Othmar Pfannes, Ph.D., CEO of Genedata. “We are pleased to see that our integrated R&D workflow platform helps our rapidly growing customer base to reduce R&D process complexity, thereby enabling a cost-efficient development of innovative drugs that will help patients worldwide.”

About Genedata

Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI in their R&D, spanning early discovery all the way to the clinic. Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US.

http://www.genedata.com

LinkedIn | Twitter | YouTube

________________________________________

Contact

Miles Fisher-Pollard

Genedata

Public Relations

Phone: +41 61 511 85 61

pr@genedata.com

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company’s products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Share article on social media or email:



Health: Mental Health

The New England Center for Children Hosts Legislators’ Day to Raise Awareness of Private Special Education Schools

Leave a comment


Vincent Strully, President and CEO of The New England Center for Children, with Massachusetts State Representatives Kate Hogan (D-3rd Middlesex District)

“All of us at NECC are honored to host these Massachusetts state legislators,” said Vincent Strully, President and CEO of NECC. “With the State’s support and the work of dedicated teachers and parents throughout Massachusetts, all of us can help transform the lives of children with special needs.”


SOUTHBOROUGH, Mass. (PRWEB)

The New England Center for Children® (NECC®), a global leader in education and research for children with autism, announced today a successful Legislators’ Day on Dec. 13 in which six Massachusetts State Representatives visited NECC to learn about the unique needs of private special education schools, also known as Chapter 766 schools.

Attending the Legislators’ Day were State Representatives Kate Hogan (D-3rd Middlesex District), Carmine Gentile (D-13th Middlesex District), Hannah Kane (R-11th Worcester District), David Muradian, Jr. (R-9th Worcester District), Legislative Aide Ben Kaplan for Representative Carolyn Dykema (D-8th Middlesex), and Legislative Aide Danillo Sena for Senator James Eldridge (D-Middlesex and Worcester Districts).

The Representatives observed NECC’s transformative teaching, research and technology for children with autism. They received a tour, met with administrators, teachers and students, and learned about the funding issues of special needs schools from Elizabeth Becker, Executive Director of The Massachusetts Association of Chapter 766 Approved Private Schools (MAAPS).

Chapter 766 schools (referring to the Massachusetts law that guarantees the educational rights of children with special needs) are private special education schools for children whose educational needs are beyond what can be offered in their local public schools. Funding is provided by the State.

“It was important to me as a lawmaker to meet with New England Center for Children (NECC) students, faculty, and staff at their Legislators’ Day and experience first-hand the inclusive learning environment they provide for students right here in our community,” said Representative Kate Hogan (D-Stow). “NECC is a steward of the Commonwealth’s commitment to reaching each and every student with educational excellence – working with passion and expertise to break down barriers to opportunity for exceptional learners and students living with autism.”

“All of us at NECC are honored to host these Massachusetts state legislators. Special education and Chapter 766 schools must remain a priority for Massachusetts,” said Vincent Strully, President and CEO of NECC. “With the State’s support and the work of dedicated teachers and parents throughout Massachusetts, all of us can help transform the lives of children with special needs.”

“It is always special to have Massachusetts state legislators take the time to visit our member schools,” said Elizabeth Becker, Executive Director of The Massachusetts Association of Chapter 766 Approved Private Schools (MAAPS). “Meeting students and speaking with a few of the hundreds of employees about their experience at The New England Center for Children was incredibly meaningful. NECC has not only changed thousands of lives, it has changed the entire field of education around autism spectrum disorder. Massachusetts is lucky to be the founding site for this special school.”

The legislators also learned about NECC’s graduate-level teacher training program, which educates tomorrow’s teachers in best practices that will benefit students in Massachusetts classrooms and beyond. NECC also partners with public schools in Massachusetts to provide classrooms that apply behavioral principles that mirror the structure and support often found only in private school settings. NECC consultants work with public schools to design effective solutions to improve student progress and increase independence.

About The New England Center for Children

The New England Center for Children® (NECC®) is an award-winning autism education center and research institute. Our community of teachers, researchers, and clinicians have transformed the lives of thousands of children with autism worldwide through education, research, and technology. The Center provides comprehensive services to maximize independence: home-based, day, and residential programs, partner classrooms in public school systems, consulting services, the ACE® ABA Software System (http://www.acenecc.org), teacher professional development, and research on educational best practices.

NECC is committed to staff professional development, partnering with local colleges to provide on-site graduate training and degrees at little to no cost to the NECC teacher. The result is a growing pool of exceptional teachers trained in best-in-class methodologies, whether they continue their careers at NECC or move on to public schools or private agencies. The New England Center for Children is based in Southborough, MA, and operates a center in Abu Dhabi, UAE. Learn more at http://www.necc.org.

Share article on social media or email:

Health: Abortion

Reed Tech Selected by The Vision Council as the full-service solution for UDI

Leave a comment


Reed Tech continues to evolve to meet business critical needs of medical device manufacturers, such as vision products. We provide a single, reliable data repository, accessible across departments wherever they are located,” said Arshad Rahman, General Manager of Reed Tech Life Sciences.


HORSHAM, Pa. (PRWEB)

Reed Technology and Information Services Inc. (Reed Tech™), a leading provider of data management and analytics solutions for the life sciences industry, is proud to be recognized by The Vision Council, the leading non-profit organization serving as a global voice for eyewear and eyecare, as a provider solution for their association members. Reed Tech offers a full-service solution for medical device manufacturers to manage regulatory and commercial product information, including Unique Device Identifier (UDI) submissions to the European Union Databank on Medical Devices (EUDAMED).

Regulatory product data submissions for the UDI requirements due in 2020 require planning and expertise. The FDA Class I UDI requirements for labeling, direct marking and AccessGUDID submission are due next September. Additionally, for those manufacturers intending to market prescription eyewear products in the European Union, EUDAMED submission will be due in May 2022. Additional global regulators are emerging and will require regulatory expertise for UDI submissions.

“Reed Tech is delighted to be recognized by The Vision Council as they build awareness among their members for upcoming UDI product data management needs. Looking to the future, more global requirements will arise as additional health authorities around the world publish UDI regulations. Reed Tech SingleSource™ for Medical Devices continues to evolve to meet business critical needs of medical device manufacturers, such as vision products. Reed Tech provides a single and reliable data repository, accessible across departments wherever they are located in the world,” said Arshad Rahman, General Manager of the Reed Tech Life Sciences division.

“The Vision Council aims to provide its members with the best resources so they can run a successful business, and we are confident our collaboration with Reed Tech will accomplish this goal,” said Michael C. Vitale, ABOM, The Vision Council’s senior technical director and Lens Division liaison. “Adhering to the UDI requirements is critical for our members, so we are greatly looking forward to utilizing the full-service solution from Reed Tech in the optical industry.”

About Reed Tech:

Reed Tech is the provider of best-in-class data management, conversion, information, and analytics solutions to government agencies, patent-driven companies and law firms, and the life sciences industry. Our solutions offer the means for our customers to increase productivity, comply with regulations and make more informed decisions quickly. Our offerings enable the collection, transformation, submission and analysis of data. The corporate culture is driven by a commitment to excellence, innovation, and a strong dedication to customers, employees and communities. Reed Tech is a LexisNexis® company. For more information, please visit ReedTech.com

About The Vision Council:

Championing better vision for better lives, The Vision Council positions its members for success by promoting growth in the vision care industry through education, advocacy, research, consumer outreach, building strategic relationships and industry forums. By sharing the latest in eyewear trends, advances in technology and advice from eyewear experts, The Vision Council serves as a resource to the public looking to learn more about options in eyeglasses and sunglasses. For more information, visit TheVisionCouncil.org

Share article on social media or email:

Health

EnSoftek continues to expand its flagship DrCloudEHR™ solution with the release of its latest best practice module, Activities of Daily Living (ADL)

Leave a comment


DrCloudEHR Activities of Daily Living (ADL) Module

“We consistently seek to develop easy to use solutions that are the right fit for our Customers and we are excited to release our latest ADL module which complements our DrCloudEHR suit of best practice solutions” said Ramana Reddy, CEO of EnSoftek.


BEAVERTON, Ore. (PRWEB)

In another release to prepare our Customers for Person Centered Care in a Value Based Reimbursement (VBR) market, EnSoftek announces the release of its latest best practice module for the DrCloudEHR solution, Activities of Daily Living (ADL). The DrCloudEHR ADL module offers agencies a simplified option to document services delivered as part of an individual’s activities of daily living. A fast and easy to use solution requiring minimal training, this module allows non-technical staff (direct service providers and other support staff) to quickly look up an individual, document services, and record associated interventions including the level of support provided.

DrCloudEHR Activities of Daily Living (ADL) module ensures that individual records are being completed and maintained in a timely and accurate manner, from which, data can then be used to analyze care improvement, an absolute requirement for achieving best levels of VBR.

“EnSoftek is committed to providing the highest level of care through its DrCloudEHR solution to Behavioral Health and Human Services organizations. As a result of our continued efforts in listening closely to the needs of our partners, we consistently seek to develop easy to use solutions that are the right fit for our Customers and we are excited to release our latest Activities of Daily Living (ADL) module which complements our DrCloudEHR suit of best practice solutions” said Ramana Reddy, President/CEO of EnSoftek.

About DrCloudEHR™ and EnSoftek, Inc.

Currently in use in 26 states throughout the country, DrCloudEHR from EnSoftek is a meaningful use stage 3 certified (supporting Interoperability), native cloud electronic health records (EHR) system designed for behavioral health and human services organizations. DrCloudEHR, available with anytime, anywhere access, helps our customers deliver better services, improve patient care, engagement, health outcomes; and provide better overall patient satisfaction – making it the preferred solution for current and future behavioral health, health and human services, and integrated care providers.

EnSoftek, Inc. provides diversified enterprise IT solutions to both public and private sector enterprises.

Follow us on Twitter, LinkedIn, and Facebook.

http://www.drcloudehr.com ; http://www.ensoftek.com

Share article on social media or email:

health and fitness

Highmark Fights Opioid Stigma, Promotes Workplace Recovery with Shatterproof

Leave a comment


Our collaboration with Shatterproof will help fight stigma so that opioid use disorder is viewed as a chronic disease, rather than a moral failing. –Highmark president Deb Rice-Johnson


Pittsburgh, Pennsylvania (PRWEB)

Highmark announced that its employer-based members have access to new virtual education and advocacy tools that combat stigma associated with opioid use disorder (OUD) and promote recovery in the workplace. These new resources, which are a value-added service for Highmark group customers in Pennsylvania, Delaware and West Virginia, are offered in collaboration with Shatterproof. Shatterproof is a national nonprofit organization dedicated to reversing the addiction crisis in the U.S.

“Across the communities that we serve, we found that stigma associated with opioid use disorder is widespread,” says Highmark president Deb Rice-Johnson. “And yet, despite that stigma, we found that people want to help someone who is struggling with opioid dependence. Our collaboration with Shatterproof will help fight stigma so that opioid use disorder is viewed as a chronic disease, rather than a moral failing. It will also equip workplaces and our members with the knowledge and resources to start a conversation about opioids and help those in need.”

Through Shatterproof, Highmark’s employer-based members can engage in brief, interactive education modules that explore the science of opioid use disorder; environmental and genetic risk factors; the dangers of opioids; signs, symptoms and evidence-based treatment options; ways to help individuals and families challenged by OUD; and success stories of individuals who are in recovery.

These modules, which take around five minutes each to complete, also provide supplemental videos, fact sheets and other evidence-based resources for those who want a deeper dive on each subject.

“As the opioid crisis has evolved, so has our response,” says Dr. Caesar DeLeo, vice president and executive medical director of strategic initiatives for Highmark. “We remain committed to helping the members and communities that we serve at all stages—from fighting stigma, to preventing dependence, to accessing treatment, to promoting long-term recovery that allows individuals to return to their family lives and the workforce.”

For more information, please visit: https://justfive.org/highmarkblueshield/

The collaboration with Shatterproof is a response to the results of a 2019 community survey that Highmark conducted in each of its core health insurance markets in Pennsylvania, Delaware and West Virginia to better understand the public’s attitudes toward and experiences with opioid dependence. In each of Highmark’s core markets, more than 80 percent of survey respondents said that opioid dependence is mostly or somewhat the fault of the person. Additionally, more than three-quarters of respondents in all markets said that it is important for them to encourage friends, family members or acquaintances to seek care for opioid dependence.

Substance use disorders have wide-ranging consequences for employers, creating challenges related to decreased workplace safety and productivity, increased health care costs, absenteeism, turnover and a smaller pool of available talent. Substance use disorders have an estimated economic impact of more than $400 billion annually in the U.S., according to the National Safety Council (NSC). Large U.S. employers spent more than $2.5 billion annually in recent years on treatment for OUD and opioid overdoses. More than two-third of individuals with OUD are in the workforce, according to the NSC.

The collaboration with Shatterproof continues Highmark’s leadership in responding to the opioid crisis with a comprehensive approach that emphasizes primary prevention, safe prescribing and community supports.

Highmark has implemented a progressively intensive strategy to address the opioid crisis. The first component focuses on prevention by offering effective, non-pharmaceutical pain management therapies at the site of care. The second component of Highmark’s strategy emphasizes safe opioid utilization through new evidence-based medication policies, as well as ongoing monitoring and educational efforts for both members and prescribers. Highmark uses a data-driven approach to monitor members’ prescribing patterns and identify potentially unsafe use of opioids and other controlled substances. The third component centers on identifying members with opioid use disorder and linking them with high-quality, accessible treatment programs. Through these efforts, Highmark has reduced its members’ use and duration of use of opioids.

Throughout the past three years, Highmark and the Highmark Foundation have provided $3 million to community organizations and programs fighting the opioid epidemic in Pennsylvania, Delaware and West Virginia. Recently, Highmark’s Financial Investigations and Provider Review Team was honored with the National Health Care Anti-Fraud Association’s Excellence in Public Awareness Award for its Opioid Epidemic Education Program. Through that program, more than 6,500 students, parents and educators in western PA have been empowered with knowledge and resources to respond to opioid dependence in their communities.

About Highmark Inc.

One of America’s leading health insurance organizations and an independent licensee of the Blue Cross Blue Shield Association, Highmark Inc. (the Health Plan) and its affiliated health plans (collectively, the Health Plans) work passionately to deliver high-quality, accessible, understandable, and affordable experiences, outcomes, and solutions to customers. As the fourth-largest overall Blue Cross Blue Shield-affiliated organization, Highmark Inc. and its Blue-branded affiliates proudly cover the insurance needs of 4.5 million members in Pennsylvania, Delaware, and West Virginia. Its diversified businesses serve group customer and individual needs across the United States through dental insurance, vision care and other related businesses. For more information, visit http://www.highmark.com.

###

Share article on social media or email:

Industry: Healthcare

HealthSherpa enrolls over 1 million Americans during Open Enrollment Period

Leave a comment



SAN FRANCISCO (PRWEB)

With the close of the open enrollment period in the 38 states using the federal health insurance Marketplace, HealthSherpa announced its 2020 open enrollment results.

Between November 1st and December 17th, 2019, HealthSherpa enrolled 1.2 Million people in ACA coverage – a 143% increase over the prior Open Enrollment period. Over 31,000 of these enrollees were able to take advantage of the deadline extension granted by the Centers for Medicare and Medicaid Services. In total, HealthSherpa accounted for over 14% of ACA enrollments across the 38 Federal Marketplace states.

Most HealthSherpa consumers found coverage for $47/month or less, and 72% enrolled in silver plans, which offer comparable coverage to employer-sponsored health insurance. In aggregate, HealthSherpa has enrolled over 3 million Americans in on-exchange health insurance since 2014.

HealthSherpa is one of a handful of companies approved to use the Department of Health and Human Services’ innovative new Enhanced Direct Enrollment (EDE) technology, and was the first company granted approval on November 28th, 2018. In the 2020 Open Enrollment Period, HealthSherpa hosted the EDE platform for 37,000 insurance agents and over 15 insurance carriers.

EDE permits private companies to carry out all enrollment and related activities for on-exchange health coverage. HealthSherpa is approved for Phase 3, which allows HealthSherpa to process all applications, including those for rare tax circumstances, end-to-end on HealthSherpa.com.

“Continued strong enrollment year over year shows that consumers and issuers alike are deeply invested in the ACA Marketplace,” said HealthSherpa CEO George Kalogeropoulos. “Technologies like Enhanced Direct Enrollment are making it easier than ever for issuers, agents, employers, and other stakeholders to help Americans enroll in comprehensive coverage, and to help them manage that coverage throughout the year. We are proud to be at the forefront of ACA enrollment and to have the privilege of helping millions of Americans access the peace of mind that can only come with high-quality, ACA-compliant coverage.”

About HealthSherpa

HealthSherpa partners with large employers, insurers, as well as insurance agencies and agents to support consumers searching for, enrolling in and utilizing high quality, affordable health insurance coverage. HealthSherpa only sells ACA marketplace plans, which have built-in consumer protections, and since its founding in 2014, has enrolled over 3 million Americans in Affordable Care Act coverage. For more information, visit http://www.healthsherpa.com.

Share article on social media or email:

Health

NeoTract Designates Dr. Timothy Posey as UroLift® Center of Excellence

Leave a comment


News Image

“This designation recognizes Dr. Timothy Posey as a UroLift Center of Excellence for his commitment to providing safe and effective treatment to patients with BPH,” said Dave Amerson


PLEASANTON, Calif. (PRWEB)

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Timothy Posey, MD, Urologic in Tupelo, MS, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Posey has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“This designation recognizes Dr. Timothy Posey as a UroLift Center of Excellence for his commitment to providing safe and effective treatment to patients with BPH,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “We are pleased to see the continued acceptance of the UroLift System as a standard of care treatment that may allow men to discontinue the use of BPH medications and improve their quality of life.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

# # #

For Teleflex Incorporated:

Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504

nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2.McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

health and fitness

Alloy Personal Training Franchise announces their first major development deal with several more deals imminent

Leave a comment


Alloy Personal Training Office

“Our nearly 30 years of experience coupled with the thousands of gyms we’ve worked with through our Alloy licensing company have given us a great business model for our partners,” says Alloy CEO Rick Mayo.


ROSWELL, Ga. (PRWEB)

Alloy Personal Training Franchise announced that they have awarded their first major development deal with several more deals imminent.

Alloy Personal Training, an award-winning personal training fitness business, launched their new franchise opportunity, Alloy Personal Training in September 2019, with a vision to provide a superior personal training franchise solution that is uniquely focused to serve the ever-growing “active aging” population, specifically those 50 years and older.

“We are excited to award our first franchise and have several other candidates that are in the final stages,” says Alloy CEO Rick Mayo. “Our nearly 30 years of experience coupled with the thousands of gyms we’ve worked with through our Alloy licensing company have given us a great business model for our partners.”

While The Alloy Personal Training Franchise Opportunity is just over four months old, the Alloy systems, platforms, and know-how have already been used to serve millions of members in thousands of fitness facilities around the world and was recently awarded the AFS Fitness Business of the Year.

“We have spent the last few years making significant changes to our previous fitness program license model to become a personal training franchise opportunity,” says Suzanne Robb, COO of Alloy Personal Training. “Our mission is to take our unique personal training system and build a personal training franchise that is strong, durable, and timeless. We believe the personal training and fitness industry needs an overhaul, and we want to be the force to make it happen.”

“The Alloy Personal Training Franchise opportunity includes everything that we have learned to own and operate a successful Personal Training Fitness Business,” says Tony Chemer, VP of Franchise Sales, “it allows us to provide total support for our business partners with all of the details required from build-out design, equipment, fitness operations, marketing, and the specifications of our systems that are already proven in thousands of gyms worldwide.”

Discovery days are underway, and territories are now being awarded. The Alloy systems are well developed, and focusing on discreet segments.

About Alloy Personal Training Franchise:

The Alloy Personal Training fitness program was created in 1992 around a very straightforward philosophy: people who get personalized coaching get better results. Today, Alloy programs are among the most effective programs in the world for helping people, especially those over 50, who want to look and feel their absolute best.

Alloy’s established, effective fitness platform and business management solutions have delivered real results throughout the world. Alloy Personal Training Franchise gives franchisees the chance to make an impact, both on their community and their future with a branded, brick-and-mortar Alloy personal training franchise location.

Share article on social media or email: